Michelle S. Ludwig, MD, MPH, PhD
Investigators are exploring concurrent PARP inhibition and definitive regional radiotherapy in patients with metastatic invasive cervical cancer in an ongoing phase I/II study (NCT03644342).1,2
Niraparib, an oral targeted therapy, has demonstrated benefit in breast and ovarian cancers and is indicated for use as maintenance therapy in adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete response or PR to platinum-based chemotherapy. In October 2019, niraparib was also approved for use in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with ≥3 prior chemotherapy regimens, and whose cancer is associated with homologous recombination deficiency–positive status.
- Baylor recruiting participants for cervical cancer clinical trial [news release]: Houston, TX. Baylor College of Medicine. Published January 29, 2020. https://bit.ly/38HyjEw. Accessed February 11, 2020.
- Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix (NIVIX). https://clinicaltrials.gov/ct2/show/results/NCT03644342?view=results. Updated August 23, 2018. Updated December 5, 2019. Accessed February 11, 2020.
... to read the full story